Myocardial Infarction Study (FAMIS) was a 2-year randomized, double-blind, placebo-controlled multicenter study investigating the hemodynamic and clinical effects of early (< 9 h from onset of symptoms) administration of fosinopril in 285 patients with anterior AMI undergoing thrombolysis within 6 h of symptom onset. The objective of the study was twofold: 1) to estimate changes in left ventricular (LV) volumes and function over 3 months by a series of echocardiographic evaluations, and 2) to clinically assess mortality and the occurrence of congestive heart failure (CHF) over 2 years. LV volumes measured at baseline (24 to 48 h from symptom onset) were within the normal range in over twothirds of randomized patients, and the changes in volume were comparable after 3 months of treatment with either fosinopril or placebo. However, fosinopril-treated patients showed a 30% reduction in the 2-year incidence of death or moderate-to-severe CHF (P ‫؍‬ .04) despite having a worst prognostic profile at baseline. This benefit of fosinopril was confirmed in the subgroup of patients without CHF on admission, who showed a 34.1% reduction in the 2-year occurrence of CHF (P ‫؍‬ .05) and a 29. A cute myocardial infarction (AMI) is responsible for dysfunction and remodeling of the left ventricle (LV), which results in progressive ventricular dilatation, 1,2 systolic dysfunction, development of heart failure, 3 and increased mortality. 4 Therefore, prevention of LV dysfunction must be considered a major objective in patients with AMI. Thrombolytic treatment is widely used in patients with AMI, where it reduces infarct size, improves LV function, and prolongs survival.
However, the benefit of early thrombolysis is enhanced by the concomitant use of drugs that do more than simply improve LV function. 6, 7 Angiotensin converting enzyme (ACE) inhibitors reduce mortality and morbidity when given to patients with AMI 8 -12 independent of the effect of concomitant thrombolytic treatment. 8, 11, 13 In particular, ACE inhibitors prevent the progressive LV remodeling that follows AMI 14, 15 by days to months, thus leading to an improvement in the patient's long-term clinical outcome. When administered during the acute phase of AMI, ACE inhibitors also reduce early in-hospital mortality, 9, 11, 13 suggesting a cardioprotective effect unrelated to the prevention of LV remodeling, which occurs after longer periods of therapy.
These findings suggest that early use of ACE inhibitors could substantially improve the clinical outcome of patients with AMI who receive thrombolysis. In particular, the concomitant effects of ACE inhibitors and thrombolytic drugs on the recovery of LV function, as well as the additional cardioprotective effects of ACE inhibitors, might result in late clinical benefit that could extend to patients who do not have LV dysfunction during the early postinfarction period. Trials studying the long-term effects of ACE inhibitors in patients with AMI have been carried out primarily in patients who did not receive thrombolysis or who had early reductions in LV ejection fractions. 16 -23 Conversely, the effects of ACE inhibitors have been poorly investigated in patients with a preserved LV function after AMI, despite the fact that this group represents a large number of patients. Indeed, wide use of aggressive pharmacological therapy has considerably increased the number of patients with normal LV function who often do not receive any long-term treatment, despite recent reports that these patients may develop late LV remodeling. 24 These observations raise the question of whether ACE inhibitors can play a role in extending the benefits achieved with fibrinolysis.
Two previous studies have indirectly addressed this issue 6, 25 and suggested that the clinical outcome in patients with AMI undergoing thrombolysis can be improved independently of a significant change in LV volumes and function. These findings again suggest that ACE inhibitors can exert a benefit in patients with AMI through activation of mechanisms partially independent of LV remodeling. These stimulating results provided the rationale for investigating whether early treatment with ACE inhibitors would produce longterm improvement in clinical outcome of patients with marginal LV dysfunction after MI. In particular, the Fosinopril in Acute Myocardial Infarction Study (FA-MIS) was developed to investigate the effects of acute treatment with an ACE inhibitor on the progression of LV dilatation, as well as on long-term clinical outcomes in patients with anterior AMI receiving early intravenous thrombolysis.
METHODS

Study Organization
The FAMIS study 26 was a randomized, double-blind, placebo-controlled, multicenter trial involving 285 patients with an anterior AMI who received thrombolytic treatment with intravenous recombinant tissue-type plasminogen activator (iv rt-PA) within 9 h of the onset of symptoms. Patients were enrolled at 16 centers in Italy (see Appendix). The study was conducted in agreement with the Declaration of Helsinki (Hong Kong Revision, 1989) and the protocol was approved by the Institutional Review Board of the University of Bologna, Italy, as well as by the local ethical committees when required. All the patients provided informed consent before randomization.
Patients Patients of either sex, aged 18 to 75 years, were eligible for enrollment if they presented to the intensive care unit within 9 h of the onset of typical ischemic chest pain associated with electrocardiographic signs of definite anterior wall MI and if they were eligible for thrombolytic treatment. Patients were excluded from the study if they had one of the following: (1) Killip class IV on admission, (2) supine systolic blood pressure Ͻ 100 mm Hg on admission, (3) serum creatinine level Ͼ2.1 mg/dL, (4) previous history of congestive heart failure (CHF), (5) coronary artery bypass graft (CABG) within 3 months prior to study entry, (6) current treatment with ACE inhibitors, (7) contraindications to the use of ACE inhibitors, or (8) inability or refusal to give informed consent. All potentially eligible patients received usual therapy, including ␤-blockers and aspirin. Analgesic agents, nitrates, calcium antagonists, inotropic drugs, diuretics, and anticoagulants were given if indicated.
Study Drug, Dose Titration, and Follow-Up The study drug, fosinopril sodium (Bristol-Myers Squibb, Princeton, NJ), is a prodrug with a compensatory dual route of excretion (hepatic and renal), whose characteristics have been thoroughly described. 27, 28 Fosinopril was given at an initial dose of 5 mg, which was repeated after 24 h and then progressively doubled to a final target dose of 20 mg once daily if systolic blood pressure was Ͼ100 mm Hg and if there were no signs or symptoms of hypotension. Patients were evaluated on admission to the Cardiac Care Unit, on discharge (15 Ϯ 3 days), and at the end of the active follow-up period (3 months Ϯ 7 days). Twenty-four to 48 hours after symptom onset, as well as on discharge and after 3 months, patients underwent a two-dimensional (2-D) echocardiographic evaluation to assess LV volumes and function. Upon completion of the 3-month double-blind period, the study medication was stopped and patients were then maintained on their other therapy for an average of 24 Ϯ 5 months (range 2 to 35 months) in an open manner. During this time, patients were followed-up to assess the prevalence of major cardiovascular events (death and CHF).
Study End Points
The primary objective of the FA-MIS study was to evaluate the safety and efficacy of fosinopril in preventing an increase in LV volumes after 3 months in patients with anterior MI. Prospectively defined secondary outcomes for the study were 1) the efficacy of fosinopril in reducing the long-term occurrence of death or moderate-to-severe CHF in patients with anterior AMI, and 2) the efficacy of fosinopril in reducing the long-term occurrence of the same events in patients who did not initially develop acute CHF at the time of the infarctions.
Echocardiographic Measurements A complete echocardiographic examination was performed on admission (24 to 48 h from onset of symptoms), before discharge, and after 3 months of double-blind treatment. The initial examination was performed at least 12 h after the previous dose of study medication, and those scheduled at discharge and after 3 months were conducted 18 to 30 h after the previous dose of study medication and 72 to 96 h after the withdrawal of study medication, respectively. An additional echocardiographic evaluation was also obtained if it was thought that the patient would not complete the 3-month period of double-blind treatment (eg, due to side effects of drugs, the need for coronary artery bypass graft [CABG] , or percutaneous transluminal angioplasty [PCTA] ). Blood pressure and heart rate were recorded before each examination. All the echocardiograms were analyzed at a central laboratory (Echo Core Laboratory, Verona, Italy) and the analysis was performed by fully blinded echo readers who were unaware of either the treatment assignment or the echocardiogram sequence.
A quantitative analysis of LV volumes was performed using a commercially available computer system (Cardio 500, Kontron) and all the examinations for each patient were analyzed by the same reader. The endocardial boundary of the LV cavity was identified and traced by a light-pen system in the apical fourand two-chamber views from ECG-gated images frozen at end-diastole (onset of QRS) and at end-systole (the subsequent frame with smallest LV cavity area). The end-diastolic and end-systolic LV volumes were computed by using a modified Simpson's rule technique 29, 30 in which each of the two digitalized plans was divided into 30 segments. Stroke volume was computed as: end-diastolic volume Ϫ end-systolic volume. Ejection fraction was calculated as: [stroke volume/end-diastolic volume] ϫ 100.
During the study, two random samples of 10% of the recorded echocardiograms were reevaluated after 6 months by the two readers under the control of an independent consultant. The difference between the first and the second reading was consistently within a range of Ϯ5%.
Enzymatic Infarct Size Infarct size was estimated from the release of creatinine kinase and creatine kinase-MB calculated from serial blood samples taken before thrombolysis and then twice daily during the first 3 days. Peak CK, mean CK, and the area under the curve (AUC) for CK plasma levels over time were measured.
Clinical Events Clinical events, including death and development or worsening of CHF, were noted on the patient case-record form. The presence of CHF was based on the clinical judgment of the investigators. Acute CHF on admission was defined as the concomitant presence of three of the following four signs: pulmonary congestion on chest x-ray, peripheral edema, pulmonary rales, and an S 3 gallop. Moderateto-severe CHF, included in the definition of the secondary end-point, was defined as New York Heart Association (NYHA) functional classes III to IV.
Statistical Consideration Based on available data on variance in LV volumes, as measured by two-dimensional echocardiography, 6, 19 the size for the study was estimated to be 280 patients. These assumptions were made to ensure a power exceeding 80% with a significance level of 5% (two-tailed test), allowing for 30% unavailable echocardiograms and 5% unconfirmed AMI.
The results of the study were analyzed by an independent Data Coordinating Center (Cardioricerca, Rome, Italy). Continuous variables were compared using Student's t test. The comparisons between treatments in terms of changes in LV volumes have been carried out using an analysis of variance for repeated measurements, whereas analysis of covariance has been employed to adjust the data for the differences observed in baseline characteristics. Patients having at least two readable echocardiographic evaluations were included in the analysis. Long-term follow-up data were analyzed using the original randomization assignment. Comparisons between the two treatment groups relative to the prevalence of clinical end-points (mortality and CHF) at the end of the follow-up period, were assessed by the 2 test with the MantelHaenszel extension. All analyses were performed on an intention-to-treat basis and P values are reported as one-tailed.
RESULTS
During the enrolment period of the FAMIS study, 285 patients were randomized; 143 allocated to placebo and 142 to fosinopril treatment. The time from onset of symptoms to thrombolysis was 2.8 Ϯ 1.4 h in the placebo group and 2.7 Ϯ 1.4 h in the fosinopril group. The first dose of the study medication was given 5.9 Ϯ 1.3 h and 6.0 Ϯ 1.4 h, respectively, from the onset of symptoms. Complete follow-up was obtained in 285 and 277 patients after 3 months and after 2 years of observation, respectively. Twelve patients (five placebo and seven fosinopril) having an unconfirmed AMI were excluded from the clinical evaluation, which was conducted on 264 patients.
The baseline clinical characteristics of the two groups are summarized in Table 1 . A significant increase in the occurrence of clinical signs of CHF at baseline was observed in the fosinopril patients, who also showed a higher plasma CK profile and a slightly greater occurrence of Killip class II and III (Table 2) , suggesting an imbalance in the severity of baseline clinical conditions between the two groups.
Echocardiographic Measurements Adequate measurement of LV volumes at baseline was obtained in over 75% of the patients. The mean LV end-diastolic and end-systolic volume indexes and ejection fraction were within the normal range at baseline (Table 3) and showed a slight increase during the 3 months of double-blind treatment, without any difference noted between patients treated with fosinopril and placebo ( Table 3 ). The effects of treatment on LV volumes were investigated separately in the small subgroup of patients with a reduced ejection fraction (Ͻ 45%), where treatment with fosinopril prevented the progressive LV dilatation observed in the placebo group ( Figure  1) , thus confirming previous findings on the ability of ACE inhibitors to decrease the degree of progressive ventricular remodeling in patients with impaired LV function.
Blood Pressure and Heart Rate During the titration phase of the study, blood pressure showed a significant decrease after the first dose of either treatment. The overall occurrence of hypotension was 17.4% in the placebo-treated group and 29.3% in the fosinopriltreated group (P ϭ .004). Transitory hypotension during the titration phase was reported in 11 (7.7%) patients in the placebo group and 28 (19.5%) patients in the fosinopril group (P ϭ .001). However, persistent hypotension requiring specific treatment or the withdrawal of study medication occurred in the same proportion of patients in the placebo (9.8%) and fosinopril groups (9.7%, P ϭ NS).
Mortality and Occurrence of CHF
The cumulative mortality was not significantly different between the two treatment groups after either 3 months or 2 years, despite a worse prognostic profile for patients in the fosinopril group at baseline. The cumulative occurrence of CHF was slightly, but not significantly, reduced in fosinopril-treated patients, who showed a lower occurrence of moderate-to-severe CHF (NYHA class III and IV) when compared with the placebo group (Class III, 7.5% v 24%, P ϭ .04; Class IV, 2.5% v 8.0%). The combined occurrence of death and CHF showed a trend toward a reduction in the fosinopril group after 2 years of follow-up (16.8% v 22.3%; risk reduction 24.7%), which was associated with a reduction in the time-to-event interval for death or CHF (134 Ϯ 228 days in the placebo group v 182 Ϯ 272 days in the fosinopril group) that achieved borderline sta- Safety Profile Fosinopril was well tolerated in patients with AMI, with a comparable incidence of adverse events in the two groups. Cough and skin rash were observed in seven (5.2%) and three (2.2%) of those taking placebo and in eight (6.1%) and zero (0%) in patients treated with fosinopril, respectively. Serum creatinine increased significantly in eight patients (6.0%) in the placebo group and in 11 patients (8.4%) treated with fosinopril (P ϭ NS). An increase in serum potassium was observed in five (3.7%) patients treated with placebo and in six (4.6%) fosinopril-treated patients (P ϭ NS).
DISCUSSION
FAMIS has investigated the short-and long-term effects of the early use of fosinopril with thrombolysis in patients with AMI. This therapeutic strategy resulted in a large proportion of patients (about 75%) with normal LV function after AMI, and these results suggest a potential therapeutic role for the use of fosinopril after thrombolysis in such a patient population. The benefit was primarily achieved through a reduction in the development of CHF and was apparently independent of the concomitant impact on early LV remodeling. Thus, the results of the FAMIS study do not completely support prevention of progressive LV dilatation as the main mechanism of improvement in the long-term clinical outcome observed in AMI patients treated either early or late with ACE inhibitors. 14,16 -23 However, most studies investigating the effect of ACE inhibitors on LV volumes in patients with AMI have been performed either in patients who did not receive thrombotic therapy [17] [18] [19] or in patients with variable degrees of LV systolic dysfunction, 14, 15, 22 whereas the effects of ACE inhibitors and thrombolysis in patients with normal LV volumes have not been thoroughly investigated so far. Among the five trials that addressed this issue prior to the FAMIS trial, 6, 7, 25, 31, 32 significant prevention of LV dilatation was observed only by Nabel et al 7 and by Schulman et al, 31 who evaluated LV volumes in small populations of patients treated with ACE inhibitors for a short period (1 to 2 weeks). On the other hand, in three larger studies 6, 25, 32 involving about 700 patients with mean LV volumes in the normal range after treatment with thrombolysis, LV volumes were substantially unchanged after 3 to 6 months of treatment with ACE inhibitors or placebo. In this setting the results of the FAMIS study are in agreement with those of similar trials and confirm the critical role of early thrombolysis in preserving normal LV function after MI. 33 Nevertheless, the role of adjunctive therapy with ACE inhibitors can become important when thrombolysis fails to establish adequate perfusion. In the Captopril and Thrombosis in Myocardial Infarction (CAPTIN) trial, 32 the beneficial effect of ACE inhibitors with thrombolysis in preventing LV remodeling was observed only in patients who failed to show early perfusion after thrombolysis. In the FAMIS, study over 70% of the population studied had a successful reperfusion according to clinical criteria (presence of three of the following four criteria: relief of chest pain, reversal of EKG ischemic changes, rapid peak of cardiac isoenzymes, and transient arrhythmia) and successfully reperfused patients accounted for only 13% of the patients with impaired LV systolic function (ejection fraction Ͻ 40%). These findings can reasonably explain the lack of a significant effect of fosinopril on LV volumes.
However, the same findings could add a different dimension to the clinical observations of the study, applying to a common population of subjects eligible for thrombolytic treatment with a relatively good prognosis. The most interesting result of the FAMIS study is the demonstration that short-term treatment with an ACE inhibitor improves the long-term prognosis of patients with anterior AMI receiving early thrombolysis, despite no increase in LV volumes. These results are in agreement with those reported in the CATS study, 6 as well as by Darasz et al, 25 who reported a reduction in clinical events in infarcted patients treated with captopril in addition to thrombolysis, whereas LV volumes did not show any significant change. In the FAMIS study, treatment with fosinopril reduced the 2-year occurrence of death or moderate-to-severe CHF despite a greater proportion of fosinopril-treated patients with clinical signs of CHF during the in-hospital phase (Table 2) , thus supporting the ability of early fosinopril treatment to delay the progression of CHF in patients surviving an AMI.
The long-term benefit of early fosinopril treatment was confirmed in the subgroup of patients without clinical signs of CHF on admission, who showed a 30% reduction in the 2-year occurrence of CHF or combined death and CHF. These data are in agreement with our recent observations in nonthrombolyzed patients in the SMILE population 34 and suggest the ability of early administration of ACE inhibitors to prevent development of CHF over time. In particular, the results of FAMIS indicate that this benefit can also be achieved in patients undergoing early and successful thrombolysis. This favorable effect may be partially related to the physiochemical characteristics of fosinopril, which is strongly bound to both cardiac and vascular (aortic) angiotensin-converting enzymes, 35 thus influencing both cardiac structure and peripheral vascular tone.
CONCLUSION
In summary, the results of the FAMIS trial, showing modest long-term benefit in patients with AMI with early short-term fosinopril treatment on CHF, comprise one of the first demonstrations of the benefits of ACE inhibitors as interventional drugs used in addition to thrombolysis. This short-term treatment with fosinopril was not associated with a significant reduction of LV hypertrophy or an improvement in ejection fraction, suggesting that the beneficial effect observed with fosinopril may be independent of its effects on these two parameters. The FAMIS study provides important data on the short-and long-term effects of oral fosinopril started during thrombolysis in patients with anterior AMI. We suggest that the conclusions of the FAMIS study be further investigated to better under- stand the clinical potential of ACE inhibitors in treating patients with AMI.
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